Recruiting

CAMPs & Standard of Care

Sponsor:

Tiger Biosciences, LLC.

Code:

NCT06999590

Conditions

Pressure Ulcer

Ulcer

Ulcer, Pressure

Pressure Injury

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ACApatch™

caregraFT™

Standard of Care

Study Details

Brief summary:

The purpose of this study it to evaluate several cellular, acellular, and matrix-like products (CAMPs) and standard of care versus matched standard of care controls in the management of nonhealing pressure ulcers.

Conditions

Pressure Ulcer

Ulcer

Ulcer, Pressure

Pressure Injury

Study ID

NCT06999590

Start date

May 20, 2025

Status verified date

Jun, 2025

Completion date

May, 2027

Anticipated

Primary completion date

May, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. The potential subject must be at least 18 years of age or older.
2. The potential subject must agree to attend the weekly study visits required by the protocol.
3. The potential subject must be willing and able to participate in the informed consent process.
4. The potential subject must have a full-thickness pressure ulcer NPIAP stage 3 or stage 4 without exposed tendon or bone of greater than or equal to one month in duration located on the trunk (sacral, trochanteric, or ischial).
5. At enrollment, the potential subject must have a target ulcer with a minimum surface area of 2 cm2 and a maximum surface area of 100 cm2 measured post-debridement with the imaging device.
6. The potential subject has adequate off-loading of the ulcer.

Exclusion Criteria:

1. The potential subject is known to have a life expectancy of < 3 months.
2. The potential subject's target ulcer is not a pressure ulcer.
3. The target ulcer is infected, requires systemic antibiotic therapy, or there is cellulitis in the surrounding skin.
4. The target ulcer exposes tendon or bone.
5. The target ulcer has undermining or tunneling.
6. There is evidence of osteomyelitis complicating the target ulcer.
7. The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).
8. The potential subject has applied topical steroids to the ulcer surface within one month of initial screening.
9. The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.
10. The surface area of the potential subject's target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit ("historical" run-in period). Imaging Device is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable).
11. The surface area measurement of the potential subject's target ulcer decreases by 25% or more during the active 2-week screening phase: the 2 weeks from the initial screening visit (S1) to the TV-1 visit during which time the potential subject received SOC.
12. The potential subject is a woman who is pregnant or considering becoming pregnant within the next 6 months.
13. The potential subject has end stage renal disease requiring dialysis.
14. The potential subject, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.
15. The potential subject was treated with hyperbaric oxygen therapy (HBOT) or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit.
16. The potential subject has a malnutrition indicator score of <17 as measured on the Mini Nutritional Assessment.

Study Design

Enrollment

500 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: ACApatch™ + SOC

Human amniotic membrane tissue allografts derived from human placental tissue.

experimental: caregraFT™ + SOC

Human amniotic membrane tissue allografts derived from human placental tissue.

active comparator: Standard of Care

Standard of care will be cleaning, debridement, and ulcer moisture balance.

Interventions

ACApatch™

Participants will receive weekly applications of ACApatch™ and Standard of Care until ulcer closure, or a maximum of 20 weeks, whichever occurs first.

caregraFT™

Participants will receive weekly applications of caregraFT™ and Standard of Care until ulcer closure, or a maximum of 20 weeks, whichever occurs first.

Standard of Care

Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance) until ulcer closure, or a maximum of 20 weeks, whichever occurs first.

Primary outcome measure

  • Complete closure [ Time Frame: 1-20 Weeks ]

Central Contacts and Locations

Locations

Serena Group

Recruiting

Monroeville, Pennsylvania, United States, 15146

Contacts

More Information

Sponsor

Tiger Biosciences, LLC.

Last update posted

Jun 5, 2025

Last verified

Jun, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Tiger Biosciences, LLC. on 2025-06-05.